Back to Results
First PageMeta Content
Pharmaceutical industry / Research / Pharmaceuticals policy / Combination drug / Good manufacturing practice / Bioequivalence / Regulatory requirement / Committee for Medicinal Products for Human Use / Pharmacovigilance / Pharmaceutical sciences / Pharmacology / Clinical research


This report contains the collective views of an international group of experts and does not necessarily represent the decisions or the stated policy of the World Health Organization WHO Technical Report Series 929
Add to Reading List

Document Date: 2006-11-21 08:37:58

Open Document

File Size: 973,85 KB

Share Result on Facebook

City

Washington / DC / /

Company

Appendix 3 Pharmaceutical / E Table 2 (continued) Title / Table 2 (continued) Title / /

Country

United States / Canada / Australia / Botswana / /

IndustryTerm

model protocol / pharmaceutical starting materials certification scheme / estrogen/progestin drug products / pharmaceutical aspects / pharmaceutical product / entity products / pharmaceuticals / non-prescription products / combination drug product / products / chemical combinations / pharmaceutical starting materials / Fixed-combination medicinal products / active pharmaceutical ingredient / fixed-dose combination medicinal products / treatment of HIV / qualitative pharmaceutical equivalence / Fixed combination products / chemical substance / co-packaged drug products / manufacturing practices / combination drug products / pharmaceutical control laboratories / treatment of hypertension / minimum inhibitory concentration per-protocol / therapy of hypertension / antibacterial medicinal products / manufacturing practice / fixed combination medicinal products / pharmaceutical products / chemical equivalence / combination products / medicinal products / fixed dose combination drug products / comparator pharmaceutical products / qualitative chemical charaterization / /

MedicalCondition

hypertension / HIV / malaria / foremost infectious disease / Lung Disease / HIV/AIDS / human immunodeficiency virus/acquired immunodeficiency syndrome / tuberculosis / /

Organization

World Health Organization / Committee for Proprietary Medicinal Products certificate / World Bank / European Medicines Agency / United Nations / CPMP Committee for Medicinal Products for Human Use / MIC PP / European Union Food and Drug Administration / Therapeutic Goods Administration / FDA / WHO EXPERT COMMITTEE ON SPECIFICATIONS FOR PHARMACEUTICAL PREPARATIONS Thirty-ninth Report World Health Organization Geneva / Committee for Medicinal Products for Human Use / WHO Expert Committee on Specifications for Pharmaceutical Preparations / European Union / WHO Australian Institute of Health and Welfare / Harmonisation International Union of Tuberculosis and Lung Disease / /

Person

IUTLD MIC PP SPC TGA / /

Position

evaluator / Model marketing authorization letter / /

Product

pyrazinamide / isoniazid / /

ProgrammingLanguage

DC / /

RadioStation

AM 1.3 / 929 WHO / 1 WHO / 2002 WHO / /

Technology

pharmacokinetics / API / pharmacodynamics / minimum inhibitory concentration per-protocol / /

SocialTag